IL279868A - A method for the production of freeze-dried spherules containing anti-coagulation factor XIa antibody - Google Patents

A method for the production of freeze-dried spherules containing anti-coagulation factor XIa antibody

Info

Publication number
IL279868A
IL279868A IL279868A IL27986820A IL279868A IL 279868 A IL279868 A IL 279868A IL 279868 A IL279868 A IL 279868A IL 27986820 A IL27986820 A IL 27986820A IL 279868 A IL279868 A IL 279868A
Authority
IL
Israel
Prior art keywords
fxia
freeze
antibody
production
coagulation factor
Prior art date
Application number
IL279868A
Other languages
English (en)
Hebrew (he)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL279868A publication Critical patent/IL279868A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26DRYING
    • F26BDRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
    • F26B5/065Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing the product to be freeze-dried being sprayed, dispersed or pulverised
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Glanulating (AREA)
  • Drying Of Solid Materials (AREA)
IL279868A 2018-07-05 2020-12-30 A method for the production of freeze-dried spherules containing anti-coagulation factor XIa antibody IL279868A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018068250 2018-07-05
PCT/EP2019/068071 WO2020008022A1 (en) 2018-07-05 2019-07-05 METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY

Publications (1)

Publication Number Publication Date
IL279868A true IL279868A (en) 2021-03-01

Family

ID=67139764

Family Applications (2)

Application Number Title Priority Date Filing Date
IL279865A IL279865A (en) 2018-07-05 2020-12-30 A new stable high concentration formulation for anti-FXIa antibodies
IL279868A IL279868A (en) 2018-07-05 2020-12-30 A method for the production of freeze-dried spherules containing anti-coagulation factor XIa antibody

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL279865A IL279865A (en) 2018-07-05 2020-12-30 A new stable high concentration formulation for anti-FXIa antibodies

Country Status (15)

Country Link
US (2) US20210290534A1 (ko)
EP (2) EP3817723A1 (ko)
JP (2) JP2021529800A (ko)
KR (2) KR20210028673A (ko)
CN (2) CN112367975A (ko)
AR (1) AR115713A1 (ko)
AU (2) AU2019297498A1 (ko)
BR (2) BR112020026492A2 (ko)
CA (2) CA3105256A1 (ko)
IL (2) IL279865A (ko)
MX (2) MX2021000028A (ko)
PE (2) PE20210779A1 (ko)
SG (2) SG11202100028PA (ko)
TW (1) TW202034898A (ko)
WO (2) WO2020008035A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019297498A1 (en) * 2018-07-05 2021-01-21 Bayer Aktiengesellschaft Method for the production of freeze-dried pellets comprising an anti-coagulation factor xia (FXIa) antibody
EP4259200A1 (en) * 2020-12-11 2023-10-18 Boehringer Ingelheim International GmbH Formulation for multi-purpose application

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DK1794524T3 (da) 2004-07-23 2012-04-16 Bayer Technology Services Gmbh Fremgangsmåde til frysning, tørring, lagring, analysering og fyldning (SFD-SAF-fremgangsmåde) (fremgangsmåde til frysetørring af piller til parenterale biologiske lægemidler)
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
EP2578974A1 (en) * 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
EP2578975A1 (en) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Rotary drum freeze-dryer
PL2847228T3 (pl) 2012-05-10 2019-03-29 Bayer Pharma Aktiengesellschaft Przeciwciała zdolne do wiązania się z czynnikiem krzepnięcia XI i/lub jego aktywowaną postacią, czynnikiem Xla oraz ich zastosowanie
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
KR20150070384A (ko) 2012-10-25 2015-06-24 메디뮨 엘엘씨 안정한 저점도 항체 제제
EA202191513A1 (ru) 2014-10-23 2021-11-30 Эмджен Инк. Снижение вязкости фармацевтических составов
EP3167877A1 (en) * 2015-11-12 2017-05-17 Bayer Pharma Aktiengesellschaft Method for the production of freeze-dried pellets comprising factor viii
EP3443346B1 (en) * 2016-04-13 2023-08-30 Medimmune, LLC Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
EP3254671B1 (en) * 2016-06-10 2019-11-13 Octapharma AG High concentration immunoglobulin composition for pharmaceutical application
EP3559047A1 (en) * 2016-12-23 2019-10-30 Novartis AG Factor xi antibodies and methods of use
AU2019297498A1 (en) * 2018-07-05 2021-01-21 Bayer Aktiengesellschaft Method for the production of freeze-dried pellets comprising an anti-coagulation factor xia (FXIa) antibody

Also Published As

Publication number Publication date
CN112367975A (zh) 2021-02-12
SG11202100028PA (en) 2021-01-28
WO2020008022A1 (en) 2020-01-09
EP3817723A1 (en) 2021-05-12
IL279865A (en) 2021-03-01
PE20210779A1 (es) 2021-04-21
SG11202100046UA (en) 2021-02-25
JP2021529800A (ja) 2021-11-04
BR112020026492A2 (pt) 2021-04-06
EP3817727A1 (en) 2021-05-12
KR20210029221A (ko) 2021-03-15
WO2020008035A1 (en) 2020-01-09
MX2021000037A (es) 2021-03-25
AR115713A1 (es) 2021-02-17
AU2019297498A1 (en) 2021-01-21
PE20210462A1 (es) 2021-03-08
CA3105261A1 (en) 2020-01-09
MX2021000028A (es) 2021-03-09
BR112020026789A2 (pt) 2021-03-30
US20210290534A1 (en) 2021-09-23
KR20210028673A (ko) 2021-03-12
CA3105256A1 (en) 2020-01-09
JP2021529801A (ja) 2021-11-04
AU2019298656A1 (en) 2021-01-28
CN112543627A (zh) 2021-03-23
TW202034898A (zh) 2020-10-01
US20210292434A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
SG11202100317YA (en) System and method for the production of biomolecules
IL268470A (en) A method for producing multispecific antibodies
KR102100420B9 (ko) 표적특이적으로 물질을 전달하는 엑소좀의 제조방법 및 상기 방법으로 제조된 엑소좀
ZA201908158B (en) Novel method for synthesizing amanitins
EP3504276A4 (en) LIGNIN PELLETS AND METHOD FOR THE PRODUCTION THEREOF
HUE059423T2 (hu) Többlépéses folyamat a mischanthus növénybõl származó komponensek elkülönítésére
PL3586344T3 (pl) Tarcze do napromieniania do wytwarzania radioizotopów i powiązany sposób wytwarzania
SI3630738T1 (sl) Postopek za ustvarjanje ozanimoda
SG11202002498SA (en) Method of producing an electrocatalyst
IL279868A (en) A method for the production of freeze-dried spherules containing anti-coagulation factor XIa antibody
EP3563673A4 (en) PROCESS FOR INTRODUCING A SUBSTANCE INTO A PLANT
SI3672770T1 (sl) Postopek za proizvodnjo ukrivljenih pohištvenih delov
HUE060390T2 (hu) Eljárás izocianátok elõállítására gázfázisban
GB2560062B (en) Process for the production of 2-alkylalkanol from an aldehyde
EP3624137A4 (en) PROCESS FOR MANUFACTURING CERAMIC NUCLEAR FUEL IN PELLETS
RS61783B1 (sr) Integrisani postupak za proizvodnju komponenti goriva iz glicerina
EP3671762A4 (en) METHOD OF MANUFACTURING THE RADIONUCLIDE NICKEL 63
EP3847675C0 (en) PROCESS FOR THE PRODUCTION OF GALLIUM RADIONUCLIDES
SG11202013126QA (en) NOVEL HYDROXYPROPYL-ß-CYCLODEXTRIN AND PROCESS FOR THE PRODUCTION THEREOF
HUE060475T2 (hu) Eljárás izocianátok elõállítására
ZA201906270B (en) An improved method for high level production of crm
HUE050961T2 (hu) Eljárás hõálló polialkenamerek elõállítására
DK3577159T3 (da) Fremgangsmåde til fremstilling af partikler omfattende polylactid
IL289210A (en) A method for producing an antibody
GB201703384D0 (en) Process for the production of Tetraaminobiphenol macrocyclic ligands; and novel Tetraaminobiphenol macrocyclic ligands